{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T23:59:10Z","timestamp":1790207950454,"version":"4.1.0"},"reference-count":60,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,11,2]],"date-time":"2023-11-02T00:00:00Z","timestamp":1698883200000},"content-version":"am","delay-in-days":336,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01EY022097"],"award-info":[{"award-number":["R01EY022097"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01EY025286"],"award-info":[{"award-number":["R01EY025286"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Controlled Release"],"published-print":{"date-parts":[[2022,12]]},"DOI":"10.1016\/j.jconrel.2022.10.036","type":"journal-article","created":{"date-parts":[[2022,11,2]],"date-time":"2022-11-02T00:09:08Z","timestamp":1667347748000},"page":"472-484","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":47,"special_numbering":"C","title":["Six-month sustained delivery of anti-VEGF from in-situ forming hydrogel in the suprachoroidal space"],"prefix":"10.1016","volume":"352","author":[{"given":"Jae Hwan","family":"Jung","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seong Shik","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyunwoo","family":"Chung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amir","family":"Hejri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark R.","family":"Prausnitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.jconrel.2022.10.036_bb0005","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0197670","article-title":"The cost-effectiveness of bevacizumab, ranibizumab and aflibercept for the treatment of age-related macular degeneration\u2014a cost-effectiveness analysis from a societal perspective","volume":"13","author":"van Asten","year":"2018","journal-title":"PLoS One"},{"issue":"2","key":"10.1016\/j.jconrel.2022.10.036_bb0010","doi-asserted-by":"crossref","DOI":"10.1002\/btm2.10128","article-title":"Long-term therapeutic effect in nonhuman primate eye from a single injection of anti-VEGF controlled release hydrogel","volume":"4","author":"Yu","year":"2019","journal-title":"Bioeng. Transl. Med."},{"key":"10.1016\/j.jconrel.2022.10.036_bb0015","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jconrel.2016.10.026","article-title":"Single ocular injection of a sustained-release anti-VEGF delivers 6 months pharmacokinetics and efficacy in a primate laser CNV model","volume":"244","author":"Adamson","year":"2016","journal-title":"J. Control. Release"},{"issue":"10","key":"10.1016\/j.jconrel.2022.10.036_bb0020","doi-asserted-by":"crossref","first-page":"1847","DOI":"10.1097\/IAE.0000000000001493","article-title":"Systemic pharmacokinetics and pharmacodynamics of intravitreal aflibercept, bevacizumab, and ranibizumab","volume":"37","author":"Avery","year":"2017","journal-title":"Retina (Philadelphia, Pa.)"},{"issue":"8","key":"10.1016\/j.jconrel.2022.10.036_bb0025","doi-asserted-by":"crossref","first-page":"2858","DOI":"10.1021\/mp300716t","article-title":"Light-activated, in situ forming gel for sustained suprachoroidal delivery of bevacizumab","volume":"10","author":"Tyagi","year":"2013","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.jconrel.2022.10.036_bb0030","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/j.jconrel.2021.09.039","article-title":"Retinal neuroprotection by controlled release of a VCP inhibitor from self-assembled nanoparticles","volume":"339","author":"Sen","year":"2021","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2022.10.036_bb0035","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/j.actbio.2019.07.054","article-title":"Anisotropic poly (lactic-co-glycolic acid) microparticles enable sustained release of a peptide for long-term inhibition of ocular neovascularization","volume":"97","author":"Kim","year":"2019","journal-title":"Acta Biomater."},{"key":"10.1016\/j.jconrel.2022.10.036_bb0040","doi-asserted-by":"crossref","first-page":"119935","DOI":"10.1016\/j.biomaterials.2020.119935","article-title":"Sustained delivery of acriflavine from the suprachoroidal space provides long term suppression of choroidal neovascularization","volume":"243","author":"Hackett","year":"2020","journal-title":"Biomaterials"},{"issue":"11","key":"10.1016\/j.jconrel.2022.10.036_bb0045","doi-asserted-by":"crossref","first-page":"2782","DOI":"10.1021\/acs.bioconjchem.9b00475","article-title":"Hyaluronic acid-antibody fragment bioconjugates for extended ocular pharmacokinetics","volume":"30","author":"Famili","year":"2019","journal-title":"Bioconjug. Chem."},{"issue":"9","key":"10.1016\/j.jconrel.2022.10.036_bb0050","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1080\/02713683.2017.1302590","article-title":"In vivo efficacy of an injectable microsphere-hydrogel ocular drug delivery system","volume":"42","author":"Osswald","year":"2017","journal-title":"Curr. Eye Res."},{"issue":"1","key":"10.1016\/j.jconrel.2022.10.036_bb0055","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1167\/tvst.8.1.12","article-title":"Characterization of biodegradable microsphere-hydrogel ocular drug delivery system for controlled and extended release of ranibizumab","volume":"8","author":"Liu","year":"2019","journal-title":"Transl. Vis. Sci. Technol."},{"key":"10.1016\/j.jconrel.2022.10.036_bb0060","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1016\/j.jconrel.2020.01.036","article-title":"Injectable biodegradable bi-layered capsule for sustained delivery of bevacizumab in treating wet age-related macular degeneration","volume":"320","author":"Jiang","year":"2020","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2022.10.036_bb0065","series-title":"A Phase III Study to Evaluate the Port Delivery System with Ranibizumab Compared with Monthly Ranibizumab Injections in Participants with Wet Age-Related Macular Degeneration (Archway) NCT03677934","author":"ClinicalTrials.gov","year":"2020"},{"issue":"8","key":"10.1016\/j.jconrel.2022.10.036_bb0070","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1016\/j.ophtha.2019.03.036","article-title":"The port delivery system with ranibizumab for neovascular age-related macular degeneration: results from the randomized phase 2 ladder clinical trial","volume":"126","author":"Campochiaro","year":"2019","journal-title":"Ophthalmology"},{"key":"10.1016\/j.jconrel.2022.10.036_bb0075","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.jconrel.2022.03.005","article-title":"In-vitro characterization of ranibizumab release from the port delivery system","volume":"345","author":"Yohe","year":"2022","journal-title":"J. Control. Release"},{"issue":"3","key":"10.1016\/j.jconrel.2022.10.036_bb0080","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1159\/000520171","article-title":"Development of macular atrophy in patients with wet age-related macular degeneration receiving anti-VEGF treatment","volume":"245","author":"Foss","year":"2022","journal-title":"Ophthalmologica"},{"key":"10.1016\/j.jconrel.2022.10.036_bb0085","doi-asserted-by":"crossref","first-page":"1654","DOI":"10.1016\/j.drudis.2019.03.027","article-title":"Targeting drug delivery within the suprachoroidal space","volume":"24","author":"Jung","year":"2019","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.jconrel.2022.10.036_bb0090","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.jconrel.2018.03.001","article-title":"Ocular drug delivery targeted by iontophoresis in the suprachoroidal space using a microneedle","volume":"277","author":"Jung","year":"2018","journal-title":"J. Control. Release"},{"issue":"27","key":"10.1016\/j.jconrel.2022.10.036_bb0095","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.aba1606","article-title":"Suprachoroidal gene transfer with nonviral nanoparticles","volume":"6","author":"Shen","year":"2020","journal-title":"Sci. Adv."},{"issue":"15","key":"10.1016\/j.jconrel.2022.10.036_bb0100","first-page":"3299","article-title":"Suprachoroidal microinjection of bevacizumab is well tolerated in human patients","volume":"54","author":"Morales-Canton","year":"2013","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"issue":"7","key":"10.1016\/j.jconrel.2022.10.036_bb0105","doi-asserted-by":"crossref","first-page":"4749","DOI":"10.1167\/iovs.10-6291","article-title":"Pharmacokinetics of pars plana intravitreal injections versus microcannula suprachoroidal injections of bevacizumab in a porcine model","volume":"52","author":"Olsen","year":"2011","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.jconrel.2022.10.036_bb0110","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1111\/aos.14042","article-title":"Suprachoroidally injected pharmacological agents for the treatment of chorio-retinal diseases: a targeted approach","volume":"97","author":"Habot-Wilner","year":"2019","journal-title":"Acta Ophthalmol."},{"key":"10.1016\/j.jconrel.2022.10.036_bb0115","first-page":"82","article-title":"Achieving drug delivery via the suprachoroidal space","volume":"9","author":"Goldstein","year":"2014","journal-title":"Retina Today"},{"issue":"7","key":"10.1016\/j.jconrel.2022.10.036_bb0120","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1016\/j.ophtha.2020.01.006","article-title":"Efficacy and safety of Suprachoroidal CLS-TA for macular edema secondary to noninfectious uveitis: phase 3 randomized trial","volume":"127","author":"Yeh","year":"2020","journal-title":"Ophthalmology"},{"issue":"10","key":"10.1016\/j.jconrel.2022.10.036_bb0125","doi-asserted-by":"crossref","first-page":"1880","DOI":"10.1097\/IAE.0000000000002279","article-title":"Suprachoroidal injection of triamcinolone acetonide, CLS-TA, for macular edema due to noninfectious uveitis: a randomized, phase 2 study (DOGWOOD)","volume":"39","author":"Yeh","year":"2019","journal-title":"Retina (Philadelphia, Pa.)"},{"issue":"4","key":"10.1016\/j.jconrel.2022.10.036_bb0130","first-page":"320","article-title":"Suprachoroidal triamcinolone acetonide for retinal vein occlusion: results of the tanzanite study, ophthalmology","volume":"2","author":"Campochiaro","year":"2018","journal-title":"Retina"},{"issue":"2","key":"10.1016\/j.jconrel.2022.10.036_bb0135","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.ijpharm.2015.11.015","article-title":"Polyethylene glycols in oral and parenteral formulations\u2014a critical review","volume":"496","author":"Gullapalli","year":"2015","journal-title":"Int. J. Pharm."},{"issue":"4","key":"10.1016\/j.jconrel.2022.10.036_bb0140","first-page":"665","article-title":"Recent advances in hyaluronic acid-decorated nanocarriers for targeted cancer therapy","volume":"22","author":"Wickens","year":"2017","journal-title":"Drug Discov."},{"issue":"3","key":"10.1016\/j.jconrel.2022.10.036_bb0145","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1002\/term.1688","article-title":"PEG hydrogel degradation and the role of the surrounding tissue environment","volume":"9","author":"Reid","year":"2015","journal-title":"J. Tissue Eng. Regen. Med."},{"key":"10.1016\/j.jconrel.2022.10.036_bb0150","first-page":"2001908","article-title":"Drug-free, nonsurgical reduction of intraocular pressure for four months after suprachoroidal injection of hyaluronic acid hydrogel","author":"Chae","year":"2020","journal-title":"Adv. Sci."},{"issue":"1","key":"10.1016\/j.jconrel.2022.10.036_bb0155","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1167\/iovs.16-20679","article-title":"Clearance kinetics and clearance routes of molecules from the suprachoroidal space after microneedle injection","volume":"58","author":"Chiang","year":"2017","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"issue":"8","key":"10.1016\/j.jconrel.2022.10.036_bb0160","doi-asserted-by":"crossref","first-page":"2025","DOI":"10.1007\/s11095-016-1940-2","article-title":"Hydrodynamic radii of ranibizumab, aflibercept and bevacizumab measured by time-resolved phosphorescence anisotropy","volume":"33","author":"Hirvonen","year":"2016","journal-title":"Pharm. Res."},{"issue":"6","key":"10.1016\/j.jconrel.2022.10.036_bb0165","doi-asserted-by":"crossref","first-page":"1904","DOI":"10.1021\/acs.molpharmaceut.6b00069","article-title":"Hyaluronic acid molecular weight determines lung clearance and biodistribution after instillation","volume":"13","author":"Kuehl","year":"2016","journal-title":"Mol. Pharm."},{"issue":"9","key":"10.1016\/j.jconrel.2022.10.036_bb0170","doi-asserted-by":"crossref","first-page":"2941","DOI":"10.1021\/acs.molpharmaceut.5b00849","article-title":"A mechanistic model of the intravitreal pharmacokinetics of large molecules and the pharmacodynamic suppression of ocular vascular endothelial growth factor levels by ranibizumab in patients with neovascular age-related macular degeneration","volume":"13","author":"Hutton-Smith","year":"2016","journal-title":"Mol. Pharm."},{"issue":"9","key":"10.1016\/j.jconrel.2022.10.036_bb0175","doi-asserted-by":"crossref","first-page":"2996","DOI":"10.1021\/acs.molpharmaceut.6b00345","article-title":"Contribution of antibody hydrodynamic size to vitreal clearance revealed through rabbit studies using a species-matched Fab","volume":"13","author":"Shatz","year":"2016","journal-title":"Mol. Pharm."},{"issue":"5","key":"10.1016\/j.jconrel.2022.10.036_bb0180","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1177\/0885328219867974","article-title":"Employing a glutathione-s-transferase-tag and hyaluronidase to control cytokine retention and release from a hyaluronic acid hydrogel matrix","volume":"34","author":"Harui","year":"2019","journal-title":"J. Biomater. Appl."},{"issue":"2","key":"10.1016\/j.jconrel.2022.10.036_bb0185","doi-asserted-by":"crossref","first-page":"170","DOI":"10.3390\/pharmaceutics13020170","article-title":"Hyaluronidase inhibitor-incorporated cross-linked hyaluronic acid hydrogels for subcutaneous injection","volume":"13","author":"Kim","year":"2021","journal-title":"Pharmaceutics"},{"issue":"2","key":"10.1016\/j.jconrel.2022.10.036_bb0190","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1002\/jbm.a.20002","article-title":"Attachment and spreading of fibroblasts on an RGD peptide-modified injectable hyaluronan hydrogel","volume":"68","author":"Shu","year":"2004","journal-title":"J. Biomed. Mater. Res. A"},{"issue":"2","key":"10.1016\/j.jconrel.2022.10.036_bb0195","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1167\/tvst.4.2.5","article-title":"Injectable chemically crosslinked hydrogel for the controlled release of bevacizumab in vitreous: a 6-month in vivo study","volume":"4","author":"Yu","year":"2015","journal-title":"Transl. Vis. Sci. Technol."},{"key":"10.1016\/j.jconrel.2022.10.036_bb0200","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1016\/j.jconrel.2020.01.036","article-title":"Injectable biodegradable bi-layered capsule for sustained delivery of bevacizumab in treating wet age-related macular degeneration","volume":"320","author":"Jiang","year":"2020","journal-title":"J. Control. Release"},{"issue":"1","key":"10.1016\/j.jconrel.2022.10.036_bb0205","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1167\/iovs.16-20377","article-title":"Thickness and closure kinetics of the suprachoroidal space following microneedle injection of liquid formulations","volume":"58","author":"Chiang","year":"2017","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.jconrel.2022.10.036_bb0210","doi-asserted-by":"crossref","first-page":"545","DOI":"10.2147\/JEP.S308388","article-title":"Pharmacokinetics and safety of an intravitreal humanized anti-VEGF-A monoclonal antibody (PRO-169), a biosimilar candidate to bevacizumab","volume":"13","author":"Mu\u00f1oz-Villegas","year":"2021","journal-title":"J. Exp. Pharmacol."},{"issue":"8","key":"10.1016\/j.jconrel.2022.10.036_bb0215","doi-asserted-by":"crossref","first-page":"365","DOI":"10.3390\/pharmaceutics11080365","article-title":"Pharmacokinetics of intravitreal anti-VEGF drugs in age-related macular degeneration","volume":"11","author":"Garc\u00eda-Quintanilla","year":"2019","journal-title":"Pharmaceutics"},{"issue":"12","key":"10.1016\/j.jconrel.2022.10.036_bb0220","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1007\/s00417-009-1136-0","article-title":"Different properties of VEGF-antagonists: bevacizumab but not ranibizumab accumulates in RPE cells","volume":"247","author":"Klettner","year":"2009","journal-title":"Graefes Arch. Clin. Exp. Ophthalmol."},{"issue":"10","key":"10.1016\/j.jconrel.2022.10.036_bb0225","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.1136\/bjo.2008.141317","article-title":"Immunohistochemical localisation of intravitreally injected bevacizumab at the posterior pole of the primate eye: implication for the treatment of retinal vein occlusion","volume":"92","author":"Julien","year":"2008","journal-title":"Br. J. Ophthalmol."},{"issue":"12","key":"10.1016\/j.jconrel.2022.10.036_bb0230","doi-asserted-by":"crossref","first-page":"16071","DOI":"10.1038\/natrevmats.2016.71","article-title":"Designing hydrogels for controlled drug delivery","volume":"1","author":"Li","year":"2016","journal-title":"Nat. Rev. Mater."},{"key":"10.1016\/j.jconrel.2022.10.036_bb0235","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.jconrel.2016.02.041","article-title":"Sustained reduction of intraocular pressure by supraciliary delivery of brimonidine-loaded poly(lactic acid) microspheres for the treatment of glaucoma","volume":"228","author":"Chiang","year":"2016","journal-title":"J. Control. Release"},{"issue":"12\u201313","key":"10.1016\/j.jconrel.2022.10.036_bb0240","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1016\/j.addr.2006.09.004","article-title":"Hydrogels in controlled release formulations: network design and mathematical modeling","volume":"58","author":"Lin","year":"2006","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"5","key":"10.1016\/j.jconrel.2022.10.036_bb0245","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.1021\/acs.biomac.8b00140","article-title":"In situ forming, cytocompatible, and self-recoverable tough hydrogels based on dual ionic and click cross-linked alginate","volume":"19","author":"Ghanian","year":"2018","journal-title":"Biomacromolecules"},{"issue":"8","key":"10.1016\/j.jconrel.2022.10.036_bb0250","first-page":"350","article-title":"Pharmacokinetic profile of the port delivery system with ranibizumab (PDS) in the phase 3 archway trial","volume":"62","author":"Campochiaro","year":"2021","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.jconrel.2022.10.036_bb0255","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1007\/s40123-022-00532-9","article-title":"Pharmacokinetics of the port delivery system with ranibizumab in the ladder phase 2 trial for neovascular age-related macular degeneration","volume":"11","author":"Wykoff","year":"2022","journal-title":"Ophthalmol. Ther."},{"issue":"7","key":"10.1016\/j.jconrel.2022.10.036_bb0260","doi-asserted-by":"crossref","first-page":"967","DOI":"10.3390\/pharmaceutics13070967","article-title":"Drug delivery via the Suprachoroidal space for the treatment of retinal diseases","volume":"13","author":"Haim","year":"2021","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.jconrel.2022.10.036_bb0265","doi-asserted-by":"crossref","first-page":"2069","DOI":"10.1167\/iovs.17-23758","article-title":"Targeted drug delivery in the suprachoroidal space by swollen hydrogel pushing","volume":"59","author":"Jung","year":"2018","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"issue":"1","key":"10.1016\/j.jconrel.2022.10.036_bb0270","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1007\/s00417-018-4182-7","article-title":"Catheter-independent suture probe canaloplasty with suprachoroidal drainage","volume":"257","author":"Haus","year":"2019","journal-title":"Graefes Arch. Clin. Exp. Ophthalmol."},{"issue":"13","key":"10.1016\/j.jconrel.2022.10.036_bb0275","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1167\/tvst.9.13.21","article-title":"Suprachoroidally delivered DNA nanoparticles transfect retina and retinal pigment epithelium\/choroid in rabbits","volume":"9","author":"Vansara","year":"2020","journal-title":"Transl. Vis. Sci. Technol."},{"key":"10.1016\/j.jconrel.2022.10.036_bb0280","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.jddst.2018.10.028","article-title":"Mucoadhesive PEGylated inulin-based self-assembling nanoparticles: in vitro and ex vivo transcorneal permeation enhancement of corticosteroids","volume":"49","author":"Di Prima","year":"2019","journal-title":"J. Drug. Deliv. Sci. Technol."},{"issue":"8","key":"10.1016\/j.jconrel.2022.10.036_bb0285","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1634\/theoncologist.2009-0317","article-title":"Bevacizumab","volume":"15","author":"Kazazi-Hyseni","year":"2010","journal-title":"Oncologist"},{"issue":"3","key":"10.1016\/j.jconrel.2022.10.036_bb0290","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1007\/BF02850159","article-title":"A 3-month clinical trial comparing the IOP-lowering efficacy of bimatoprost and latanoprost in patients with normal-tension glaucoma","volume":"23","author":"Dirks","year":"2006","journal-title":"Adv. Ther."},{"issue":"1","key":"10.1016\/j.jconrel.2022.10.036_bb0295","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1186\/s12886-019-1284-x","article-title":"Repeated intravitreal injections of antivascular endothelial growth factor in patients with neovascular age-related macular degeneration may increase the risk of ischemic optic neuropathy","volume":"19","author":"Chen","year":"2019","journal-title":"BMC Ophthalmol."},{"issue":"2","key":"10.1016\/j.jconrel.2022.10.036_bb0300","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1007\/s40135-018-0176-1","article-title":"Endophthalmitis following intravitreal injection","volume":"6","author":"Storey","year":"2018","journal-title":"Curr. Ophthalmol. Rep."}],"container-title":["Journal of Controlled Release"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365922007064?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365922007064?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T16:36:39Z","timestamp":1759163799000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168365922007064"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12]]},"references-count":60,"alternative-id":["S0168365922007064"],"URL":"https:\/\/doi.org\/10.1016\/j.jconrel.2022.10.036","relation":{},"ISSN":["0168-3659"],"issn-type":[{"value":"0168-3659","type":"print"}],"subject":[],"published":{"date-parts":[[2022,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Six-month sustained delivery of anti-VEGF from in-situ forming hydrogel in the suprachoroidal space","name":"articletitle","label":"Article Title"},{"value":"Journal of Controlled Release","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jconrel.2022.10.036","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}